drugset
drugset / Trial / NCT00452452

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children

NCT00452452 ↗

Phase 3 Completed 355 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent Pneumococcal conjugate vaccine (13vPnC) in older infants and children who have not previously been immunized with Pneumococcal vaccine.

Timeline

Start
2007-07
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Prevnar 13 Vaccine — —

Indications

pneumococcal infection